State of Alaska Department of Revenue Trims Holdings in Lantheus Holdings, Inc. $LNTH

State of Alaska Department of Revenue cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.4% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 7,782 shares of the medical equipment provider’s stock after selling 360 shares during the quarter. State of Alaska Department of Revenue’s holdings in Lantheus were worth $637,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Westfield Capital Management Co. LP grew its position in Lantheus by 2.2% during the first quarter. Westfield Capital Management Co. LP now owns 1,589,145 shares of the medical equipment provider’s stock worth $155,101,000 after buying an additional 34,052 shares in the last quarter. Reinhart Partners LLC. grew its position in Lantheus by 16.4% during the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after buying an additional 197,719 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Lantheus by 2.3% during the first quarter. Dimensional Fund Advisors LP now owns 1,378,536 shares of the medical equipment provider’s stock worth $134,534,000 after buying an additional 31,454 shares in the last quarter. Swedbank AB grew its position in Lantheus by 11.0% during the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after buying an additional 121,500 shares in the last quarter. Finally, TD Asset Management Inc grew its position in Lantheus by 1,028.0% during the first quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider’s stock worth $66,623,000 after buying an additional 622,100 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 6,812,000 shares of company stock worth $382,427,380. 2.00% of the stock is owned by corporate insiders.

Lantheus Price Performance

LNTH opened at $51.84 on Wednesday. The stock’s 50 day simple moving average is $55.59 and its 200 day simple moving average is $75.53. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of 13.79 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The company had revenue of $378.05 million for the quarter, compared to the consensus estimate of $389.69 million. During the same quarter in the previous year, the business earned $1.80 earnings per share. Lantheus’s revenue was down 4.1% compared to the same quarter last year. As a group, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on LNTH. TD Cowen reduced their target price on Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Truist Financial set a $63.00 price objective on Lantheus and gave the company a “hold” rating in a research report on Monday, August 11th. JMP Securities reduced their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 7th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Lantheus in a research report on Saturday, September 27th. Finally, Mizuho reduced their price objective on Lantheus from $120.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, August 7th. Five equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $85.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.